El Gluten labeling and cross-contamination It has become one of the most sensitive issues in modern food safety. For people with celiac disease or gluten sensitivity, a single confusing line on the packaging can mean the difference between eating with peace of mind and suffering a reaction with serious health consequences.
While in the European Union there are already specific rules that regulate the mention «gluten-free"and the maximum permitted limits, the international debate has been reignited following the decision by the United States Food and Drug Administration (FDA) to scrutinize how the presence of gluten is reported and how it is managed cross-contact with grains that contain itWhat happens on the other side of the Atlantic can end up influencing technical criteria, interpretations and, ultimately, social and regulatory pressure within Europe and Spain.
A regulatory offensive against hidden gluten
In the United States, the FDA has taken a first formal step with the publication of a Request for Information (RFI) The focus is on labeling and preventing cross-contamination with gluten in packaged foods. This is not yet a finalized regulation, but rather a preliminary phase in which the agency is requesting specific data to support potential regulatory changes.
RFI focuses on what the agency itself calls "ingredients of interest": above all rye, barley and oatsAlthough wheat is the cereal almost automatically associated with gluten, US health authorities have made it clear that the problem is broader, and that some of the "hidden" gluten may come from other grains or from processes involving cross-contamination.
The Department of Health and Human Services, which oversees the FDA, frames this move within a broader strategy of radical transparency in labelingHealth Secretary Robert Kennedy Jr. has insisted that the public "deserves clear and reliable information about what's in their food and how it's prepared," stressing that it's not just about isolated allergies, but chronic conditions such as... Celiac Disease.
In practice, the goal is to minimize those situations in which the consumer is faced with ambiguous labels such as «modified starch", "natural flavors" or other generic concepts that may hide the presence of gluten without this being explicitly stated. For those who must follow a strict gluten-free diet, these kinds of expressions are a real trap.
What exactly does the FDA require regarding gluten labeling?
The FDA's RFI does not simply gather general opinions, but rather demands detailed evidence This will allow the problem to be assessed from a technical and epidemiological perspective. Among the information the agency wants to receive are several key aspects that are also familiar to the European context.
On the one hand, information is requested about the prevalence of products in which rye and barley are not clearly declared in the list of ingredients, despite being part of the formulation or present in compound ingredients. This issue is directly related to the debate about whether it should always be required to name the origin of certain additives or components, even when they appear in small quantities.
Another relevant chapter is that of the adverse reactions mediated by immunoglobulin E associated with rye and barley: the FDA wants to know the severity and potency of these reactions in the population, an area where it acknowledges there are currently significant data gapsThis lack of information makes it difficult to assess the real level of risk and, consequently, to decide how strict the labeling rules should be.
The agency also focuses on the oatsAlthough this cereal, in principle, does not naturally contain gluten, the problem lies in the cross-contact with grains that do contain it during planting, harvesting, transportation, or processing. The FDA wants to collect data on the actual gluten content in oat-based productsas well as the concerns of patients, professionals, and manufacturers regarding this point.
Finally, the door is opened to receiving "other related questions" and documented experiences about confusing labeling, omissions in ingredient declarations, and production practices that may pose a non-obvious risk to people sensitive to gluten. This is a direct appeal to the industry, the scientific community, healthcare professionals, and patient associations.
Data gaps and the burden on patients
One of the most striking elements of the FDA's move is that the agency itself acknowledges, unusually, that there are "serious data gaps" on the impact of these ingredients on public health. In the United States, available reports and previous reviews, including the work of the FAO and other international organizations, are not enough to construct a complete picture of the risk.
These statistical shortcomings affect several fronts: from the lack of systematic information on adverse reactions linked to contaminated rye, barley or oats, to the scarcity of studies that measure how many products actually contain these grains without declaring them transparently on the label.
FDA Commissioner Dr. Marty Makary has put words to what many people with celiac disease experience daily: they are forced to "walk on eggshells" When choosing what to eat, children often resort to guesswork based on the limited information found on packaging. This uncertainty not only leads to occasional discomfort but also increases the risk of intestinal damage and long-term complications.
Given this scenario, the RFI is presented as an opportunity for those on the front lines—patients, specialists, nutritionists, food technologists—to contribute cases, clinical data, and analyses that allow us to move beyond subjective perception. The idea is that future regulation will be based on this. solid evidence, and not just in specific instances of pressure or currents of opinion.
In Europe, where the Regulation (EU) on food information and "gluten-free" claims already establishes limits and obligations, this type of recognition of data gaps in the United States also sends a message: even with advanced regulatory frameworks, continue to refine surveillance and traceability It is an ongoing task.
From "gluten-free" marketing to real transparency
The debate opened by the FDA also points to a tension known in Spain and the rest of the EU: the gap between the commercial use of "gluten-free" claim and effective transparency in labeling. In recent years, this expression has become part of standard marketing, even for products that, by their very nature, should not contain gluten.
Meanwhile, situations persist where ingredients derived from wheat, rye, or barley appear disguised under generic names. This raises the fundamental question: To what extent should commercial simplicity be prioritized over the right to truthful and understandable information? For those who cannot consume gluten, the answer is obvious, but practical implementation encounters inertia and resistance.
US authorities have hinted at the possibility that, in the future, more explicit references may be required, such as "contains gluten" or "wheat derivative" This also applies to products where gluten is present as a byproduct, contaminant, or part of a compound ingredient. This approach aligns with the European trend of reinforcing the role of allergens on labels, requiring them to be highlighted typographically.
This shift has implications not only for patients but also for exporting manufacturers. Spanish and European companies selling in the United States could be forced to adapt their ingredient lists and production processes if additional requirements regarding gluten and cross-contamination are approved.
At the same time, the debate taking place in North America may inform reflection in the European Union on how the risks of cross-contamination are communicated, especially in oat-based products and in highly processed categories, such as snacks, prepared meals or food for groups.
Public consultation, next steps and potential impact in Europe
The FDA's RFI opens a period of public consultation During this process, any interested party can submit comments electronically or in writing. The process is designed to gather input from the food industry, scientific societies, patient organizations, healthcare professionals, and individual consumers.
With all that material on the table, the agency reserves the right to define "what kind of future regulatory measures" Measures should be adopted to better protect people with celiac disease and other gluten sensitivities. Possible scenarios include new ingredient declaration requirements, specific warnings about cross-contamination, or changes to the criteria for using the "gluten-free" label.
The United States, due to its economic and regulatory weight, often exerts a significant influence on the global industry. If gluten labeling regulations are tightened, many manufacturers operating in the European market might opt ​​to standardize their packaging, applying stricter criteria in all countries to reduce logistical complexity.
For Spain, where patient associations have been demanding a improved identification of gluten risk In catering, school cafeterias, hospitals, and law enforcement, the evolution of this process offers further arguments. Seeing that a leading regulator like the FDA acknowledges data gaps and opens the door to strengthening controls can help keep the issue on the European political and media agenda.
Ultimately, in both the United States and the EU, the challenge is the same: to transform gluten labeling from a gray area into a reliable, understandable, and truly useful tool for those who rely on it daily. If the promised transparency translates into clear rules and solid data, patients, healthcare professionals, and manufacturers will have a more predictable and secure framework for navigating an increasingly complex food market.
